175 related articles for article (PubMed ID: 28967066)
21. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
[TBL] [Abstract][Full Text] [Related]
22. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
23. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
24. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
25. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
26. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
27. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.
Liu L; Teng J; Zhang L; Cong P; Yao Y; Sun G; Liu Z; Yu T; Liu M
Biomed Res Int; 2017; 2017():2013989. PubMed ID: 28607926
[TBL] [Abstract][Full Text] [Related]
28. Differences in initial NSE levels in malignant and benign diseases of the thoracic wall.
Franjević A; Pavićević R; Bubanović G
Clin Lab; 2012; 58(3-4):245-52. PubMed ID: 22582497
[TBL] [Abstract][Full Text] [Related]
29. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
Lu QQ; Li J; Li YH; Liu H; Xie XB
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
[TBL] [Abstract][Full Text] [Related]
31. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer.
Dong Y; Zheng X; Yang Z; Sun M; Zhang G; An X; Pan L; Zhang S
J Cancer Res Ther; 2016 Oct; 12(Supplement):34-36. PubMed ID: 27721249
[TBL] [Abstract][Full Text] [Related]
32. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
33. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.
Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N
Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752
[TBL] [Abstract][Full Text] [Related]
34. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
35. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
[TBL] [Abstract][Full Text] [Related]
36. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
37. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
38. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
39. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
Li BT; Lou E; Hsu M; Yu HA; Naidoo J; Zauderer MG; Sima C; Johnson ML; Daras M; DeAngelis LM; Fleisher M; Kris MG; Azzoli CG
PLoS One; 2016; 11(1):e0146063. PubMed ID: 26730601
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
